The spectacular failure of the not-so-glitzy Muraglitazar

If you believe the conventional wisdom, it takes $800 million to develop a drug from discovery to marketing. Bristol-Meyers-Squibb just discontinued development of Muraglitazar, their PPAR agonist candidate for Type 2 diabetes. This after an _approvable letter_ from the FDA — preclinical studies, clinical studies, the submission, the whole 9 yards. I’ve put in hard hours just working on submitting a drug before, and I’m just one person out of thousands involved in development of a single compound. To get that far and get an approvable letter (i.e. “your drug is probably safe, but we need more data” ) and then discontinue must have been a hard decision.

I’d hate to be an executive in that BMS(Bristol-Meyers-Squibb) board room right now.

%d bloggers like this: